Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe for Reducing Atrial Arrhythmia Recurrence After Atrial Fibrillation Ablation
NCT07752758Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Jun 2028
01
Overview
Phase 4, randomised, single-blind trial of ezetimibe in Atrial fibrillation (AFib) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Recurrence of atrial tachyarrhythmia (≥30 seconds) after blanking period at 6 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ezetimibe
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07752758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752758.